Following the announcement of Astra-Zenica that it will start a new trial, the pharmaceutical company received a request from an unexpected source to join forces • "It is recommended to combine the two vaccines" • All details
Following the announcement by AstraZenica that it will conduct a new trial of the vaccine it has developed, Russian vaccine developers Sputnik V said tonight (Thursday) that the companies need to join forces to increase the chances of efficacy.
Archive photo: Reuters
Archive photo: Reuters
As a reminder, Russia claimed that according to interim results, its vaccine was 92% effective while the combined trial of the pharmaceutical company and Oxford University led to inconclusive results regarding its level of efficacy.
"If they are on their way to a new clinical trial, we recommend trying a combination of the two vaccines," the Russians wrote on their Twitter account.
The British-Swedish pharmaceutical company has announced that by the end of 2020 it will have about 200 million vaccine doses, of what is perceived as one of the most promising options in the virus vaccination race, due to its cheap price and its ability to be delivered at normal cooling temperatures.
Current full dose AstraZeneca regimen resulted in 62% efficacy.
If they go for a new clinical trial, we suggest trying a regimen of combining the AZ shot with the #SputnikV human adenoviral vector shot to boost efficacy.
Combining vaccines may prove important for revaccinations.
- Sputnik V (@sputnikvaccine) November 26, 2020
Meanwhile, tonight Astra-Zenica announced that it is considering another trial of a vaccine it has developed for the corona virus, in light of the unequivocal results obtained in its previous trial.
The reason for planning for the retry, is a mistake made in the previous experiment performed by the company - so some patients were given only half a dose of vaccine and not a full dose, and despite this, AstraZenica reported a 90% success rate in the experiment.
While the company claims that the experiment proves that the experiment proves that the vaccine is effective even at the low dose, many experts have questioned this.
"Now that we have found a dose that seems appropriate, we will have to test it, and conduct another experiment," the company's CEO Pascal Soriot tried to explain in the first interview since the experiment was discovered. .